Lab-Grown Coronary Bypass Graft: 2-Year Patency
Lab-Grown Coronary Bypass Graft: 2-Year Patency
Source: EACTS 2026 Annual Meeting, Barcelona | October 7–10, 2026
• Bioengineered human blood vessel developed as a potential CABG conduit.
• Human tissue vessels are grown in a bioreactor, then decellularized, leaving a natural collagen-based scaffold that can be stored until needed.
• After implantation, the patient’s own cells repopulate and endothelialize the graft, progressively converting it into living tissue.
• First reported CABG patient: graft remained patent with normal flow at 2 years, the longest reported clinical patency for this Vascudyne tissue-engineered vessel.
• No reported graft thrombosis, aneurysmal dilation, bleeding, major cardiac events, or device-related adverse events in this case.
• Potential advantage: an immediately available conduit that could avoid saphenous-vein harvesting and the second surgical wound.
• Important: this remains very early clinical evidence from a single reported patient; larger studies are required to establish long-term patency, safety, and comparison with established arterial/venous conduits.
• A European CABG feasibility study has completed enrollment.
